Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgen was one of the first companies to recognize the potential of modern biotechnology in developing valuable medicines for patients – and to assemble the diverse set of skills necessary to advance from textbook to applied science. Today, we are applying our deep scientific capabilities from more than three decades of experience to the development of biosimilars and continuing our legacy of providing patients with vital medicines. We currently have a robust pipeline with several biosimilar molecules in development which target some of the most complex and important oncology and inflammation antibody biologics.